Monitoring Agency Report for the quarter ended 31-03-2026
FISCHER · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Fischer Medical Ventures submitted its Q4FY26 Monitoring Agency Report for a preferential issue of equity shares and warrants totaling Rs. 358.46 crore. Infomerics Valuation and Rating Limited, the monitoring agency, confirmed no deviations from the stated objects of the issue. The company has raised Rs. 280.93 crore till March 31, 2026, with full utilization reported. During Q4FY26, Rs. 10.53 crore was received from conversion of 6 lakh warrants and used for partial repayment of an unsecured loan to wholly-owned subsidiary TMVIPL. Cumulative loan repayment from issue proceeds stands at Rs. 11.73 crore, with Rs. 12.97 crore still outstanding. A stock split (10:1) was effected in Q2FY26 reducing face value from Rs. 10 to Re. 1 per share. About 44.17 lakh outstanding warrants (post-split 4.42 crore) can still be exercised within 18 months from allotment.
The filing shows clean utilization of funds raised with no deviations, which is positive for investor confidence. However, shareholders should note potential dilution from outstanding warrants and that Rs. 77.52 crore of the proposed issue size remains to be raised.